Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis.
about
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markersManagement of polycythaemia vera: a critical review of current data.Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase.Experience with ruxolitinib in the treatment of polycythaemia vera.JAK2 Negative Polycythemia Vera.How I treat essential thrombocythemia.Current and future treatment options for polycythemia vera.Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary RoundtablePhiladelphia-negative chronic myeloproliferative neoplasmsClonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemiaClinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteriaJAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.Treatment options for essential thrombocythemia and polycythemia vera.The role of molecular genetic analysis within the diagnostic haemato-oncology laboratory.Erythrocytosis in children and adolescents-classification, characterization, and consensus recommendations for the diagnostic approach.Rethinking the diagnostic criteria of polycythemia vera.How common are myeloproliferative neoplasms? A systematic review and meta-analysis.Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis.Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera.European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.Investigation and Management of Erythrocytosis.Epigenetics in Myeloproliferative Neoplasms.Progression of primary myelofibrosis to polycythemia vera: A case report.Masked polycythaemia vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia vera.JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.A surprising cause of masses in the chest.JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan.Frequency of polycythemia in individuals with normal complete blood cell counts according to the new 2016 WHO classification of myeloid neoplasms.Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes.Does venous blood gas analysis provide accurate estimates of hemoglobin oxygen affinity?Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing.The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients.Masked polycythemia vera diagnosed according to WHO and BCSH classification.
P2860
Q24568313-966DACA7-CA62-4409-A462-C3F71232A67EQ24675681-666E9BE8-2E85-49DC-BD83-FFF93B11A0C3Q31009757-F316E3F4-C534-4217-A256-9ED69DF347D0Q33390032-445FA49F-91F7-4132-B4F5-59873D3D1325Q33605624-B845FC34-E386-45BD-93FB-7DAE49CE3DD6Q34578663-6BCDDADD-E488-4B23-A70D-AE4A2C44298CQ35132271-B84D01DD-AA73-42F0-BDA7-8DF61E472D3EQ35572748-FF6DCF3B-20B8-4AB7-8DBA-F349469C77E7Q36266377-CB4FE58E-7F1F-4CA3-8B8F-B2221774E214Q36283143-7E310BC4-EB7C-4F9E-A07F-BAD398E392B1Q36805833-3CAD5C45-71C2-48FA-B516-98BD03669F4EQ36874807-FC4C86BF-9C6D-4C19-AA23-826C13C80D05Q37623539-BC30003F-6BFB-4853-951A-5EF2919E09ABQ37810107-F451DD1C-0517-42C9-AF28-123AB51CF080Q37924989-E5C84C8F-A134-4B7B-BC9F-33782D26E00FQ38115285-07284A04-A586-46BC-882A-B6C9546C1BE8Q38172388-8EAC9C60-3269-4DE7-80C5-B4E0F017DBEDQ38223791-98E4EEC9-CEB1-4A90-B5A5-6C181DFD3B10Q38416243-CB876261-35D0-4285-9B10-7A499A9EBAD3Q38420817-D6C5C7BE-29EC-4AE3-BEF5-A54DF4AA2D53Q38689790-C855FBFE-858D-4540-922B-E67D46AFCDC3Q38898732-0A71B0F2-1083-4DB3-9131-768135711AA5Q39414554-9661DAA7-001B-4F48-9953-8BF9EAB1F165Q41049859-FD4947D3-5458-4842-B931-6D6751A9F648Q41085322-A4290FDE-BC84-48FC-9CF0-5A9C9F218CA3Q41545614-2DC52C81-83A2-498E-9230-50E7B8976F06Q43979129-758A3E78-03D9-4EA1-91AB-6CC9DEC8E75EQ45064976-15693748-6EF8-4180-8805-D1D1CA9E36E4Q45797468-3087A974-A027-4D5B-8835-9FBE4E683DF5Q47829592-A2BE4BB5-8CDE-430D-B825-E0E65443F72BQ50449411-6B71CB6B-E78A-46C0-9E27-E168578DF69EQ51277854-E2F8817E-579E-4736-BD07-556A64238E52Q51448317-DB58B49E-A4C3-47F0-B242-93B7049776C6Q54336750-AF7D733E-7AB9-40D8-8FEC-EFA06C7DACDBQ54376493-953D7A75-EFAA-4781-9D06-6CC5C1A2AF24Q54400423-F5279E28-1FBE-40FC-88CD-493240988F33
P2860
Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Amendment to the guideline for ...... polycythaemia/erythrocytosis.
@en
Amendment to the guideline for ...... polycythaemia/erythrocytosis.
@nl
type
label
Amendment to the guideline for ...... polycythaemia/erythrocytosis.
@en
Amendment to the guideline for ...... polycythaemia/erythrocytosis.
@nl
prefLabel
Amendment to the guideline for ...... polycythaemia/erythrocytosis.
@en
Amendment to the guideline for ...... polycythaemia/erythrocytosis.
@nl
P2093
P1476
Amendment to the guideline for ...... polycythaemia/erythrocytosis.
@en
P2093
Anthony R Green
Claire N Harrison
David Bareford
Eibhlin Conneally
John T Reilly
Mary F McMullin
National Cancer Research Institute, Myeloproliferative Disorder Subgroup
Peter Campbell
P304
P356
10.1111/J.1365-2141.2007.06741.X
P407
P577
2007-08-02T00:00:00Z